Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors With Dose Escalation and Expansion to Selected Indications

NCT04699643 is registered in ClinicalTrials.gov with EverNov Medicines (Zhuhai Hengqin) Co., Ltd as lead sponsor.

NCT NCT04699643
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04699643 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors With Dose Escalation and Expansion to Selected Indications
Lead sponsor
EverNov Medicines (Zhuhai Hengqin) Co., Ltd
Phase
Phase 1/2
Overall status
Unknown status
Start date
July 30, 2020
Completion date
June 30, 2023
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors